Evidence map›Paper›PMID 41669535›Full record

ReviewClinical kidney journal2026

Use of acetazolamide in volume overload: start at the beginning.

Nayan Arora, David H Ellison

Abstract readReview
In one paragraph

Review in Clinical kidney journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Nayan AroraDivision of Nephrology & Hypertension, Department of Medicine, Oregon Health & Science University, Portland, OR, USA.
David H EllisonDivision of Nephrology & Hypertension, Department of Medicine, Oregon Health & Science University, Portland, OR, USA.ORCID https://orcid.org/0000-0003-2915-265X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The treatment of volume overload has vexed physicians for centuries. References to herbal remedies for the treatment of fluid retention date as far back as 1550 BC in the Ebers Papyrus from Ancient Egypt [1]. The term edema originates from the Greek "to swell," and the Greek hero Oedipus, meaning "swollen foot," was so named due to the swelling of his feet from injuries inflicted by his mother to prevent the fulfillment of a prophecy. There are several references to edema in the writings of Hippocrates, with various proposed treatments, ranging from herbal remedies, purgatives, phlebotomy, and cranial decompression. The word dropsy, from the Greek word for water, originated in the Middle English period and came to describe conditions associated with an accumulation of fluid in body tissue, preceding more sophisticated knowledge of distinctive disease states. Physicians often prescribed treatments such as bloodletting, purgatives, leeches, and Southey tubes, which were invented in 1877 by English physician Reginald Southey. These were small cannulas placed in a patient's swollen extremities to relieve edema, used until the 1960s [2]. It was not until the serendipitous discovery of the diuretic properties of the mercurial agent Novasurol by Alfred Vogl, while working as a medical student at the Wenckebach clinic in Vienna, used to treat a young patient with congenital syphilis [3], that spurred the interest in synthetic diuretic agents. Despite being the first agent synthesized, acetazolamide became the "forgotten diuretic" until a recent resurgence has reinvigorated interest in its utility in patients with acute decompensated heart failure. This review will describe the background, clinical trials, and proposed utility of acetazolamide in states of volume overload.

Indexed as

diureticsheart failuremetabolic acidosisNHE3proximal tubule

Identifiers

PMID41669535
PMCPMC12883985

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.